Clinical Trial Update: SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating weekly SAR3419 in relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• SAR3419

Snippet

Sponsor: Sanofi | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED